CURRENT ISSUE

Genetic Engineering " Biotechnology News - Current Issue

(view larger image)

SUBSCRIBE

AD LINK

Visit GEN on Twitter!

Breaking News

  • Print
  • Share
  • More News

Dec 6 2006, 3:41 PM EST

Barrier Therapeutics to Participate in the 2006 RBC Capital Markets Healthcare Conference

MARKETWIRE

Dec 06, 2006 PRINCETON, NJ MARKET WIRE

Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that Geert Cauwenbergh, Ph.D., Chief Executive Officer, is scheduled to participate on the panel entitled "Skin Deep: The Future of Clinical Dermatology," being held at the 2006 RBC Capital Markets Healthcare Conference on Wednesday, December 13, 2006, beginning at 1:30 p.m. Eastern Standard Time. The conference will be held at The Westin New York at Times Square in New York City on December 13 and 14, 2006.

The panel discussion will be available live via a webcast that can be accessed through Barrier Therapeutics' corporate website at: www.barriertherapeutics.com. A replay of the webcast will be available for 30 days.

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel(TM) (ketoconazole, USP) Gel, 2%, Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including acne, psoriasis, onychomycosis and other fungal infections such as tinea versicolor. The company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at: www.barriertherapeutics.com.

Xolegel, Vusion and Solage are trademarks of Barrier Therapeutics, Inc.

Contact:
Barrier Therapeutics, Inc.
Anne M. VanLent
609-945-1202

SOURCE: Barrier Therapeutics, Inc.

  • Print
  • Share
  • More News

CAREER CENTER

Visit the GEN Career Center

for the latest biotech employment opportunities.
Start your search HERE!

visit the Career Center

WEBINARS


view all webinars

GEN and Scintellix bring you the Cryptogram Challenge: ELISA REDUX!

PODCASTS

INTERVIEW: (BIO) BANKING IN LUXEMBOURG - Interview with Robert Hewitt, Ph.D., CEO, Integrated Biobank of Luxembourg, and European Editor, Biopreservation and Biobanking (published by Mary Ann Liebert, Inc.) ...MORE

MOST POPULAR

News

Articles

Blogs